Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppresor genes in renal cell carcinoma

Journal of Clinical Pathology

Volumn 57, Issue 7, 2004, Pages 706-711

  Morris, M R ^a   Maina, E N ^a   Morgan, N V ^a   Gentle, D ^a   Astuti, D ^d   Moch, H ^b   Kishida, T ^c   Yao, M ^c   Schraml, P ^b   Richards, F M ^a   Latif, F ^a   Maher, E R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d School of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

FUMARATE HYDRATASE; HYPOXIA INDUCIBLE FACTOR 1; SUCCINATE DEHYDROGENASE; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CELL CULTURE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOLECULAR GENETICS; ONCOCYTOMA; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CARCINOMA, RENAL CELL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FUMARATE HYDRATASE; GENES, TUMOR SUPPRESSOR; HUMANS; IRON-SULFUR PROTEINS; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN SUBUNITS; REPRESSOR PROTEINS; SUCCINATE DEHYDROGENASE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 3142626559     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.011767     Document Type: Article

References (32)

1. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:987-9.
2. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169-73.
3. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
4. Clifford SC, Prowse AH, Affara NA, et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumorigenesis. Genes Chromosomes Cancer 1998;22:200-9.
5. Carmeliet P, Dor Y, Herbert J-M, et al. Role of HIF-1α in hypoxia mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
6. Maxwell PH. Oxygen homeostasis and cancer: insights from a rare disease. Clin Med 2002;2:356-62.
7. Maxwell PH. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
8. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia inducible-factor requires direct binding to the beta-domain of the Von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-7.
9. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the Von Hippel-Lindau rumour suppressor protein. J Biol Chem 2000;275:25733-41.
10. Kamura T, Sato S, Iwai K, et al. Activation of HIF1 alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 2000;97:10430-5.
11. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-61.
12. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
13. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-10.
14. Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001;357:1181-2.
15. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001b;69:49-54.
16. Gimm O, Armanios M, Dziema H, et al. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 2000;60:6822-5.
17. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. The R22X mutation of the SDHD gene in hereditary paragangliomo abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 2001;69:1186-97.
18. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1α transcriptional activity. Genes Dev 2001;15:2675-86.
19. Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-8.
20. Clifford SC, Astuti D, Hooper L, et al. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1 alpha in renal cell carcinoma. Oncogene 2001;20:5067-74.
21. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999;59:5830.
22. Jiang BH, Agani F, Passaniti A, et al. v-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997;57:5328-3.
23. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha. Genes Dev 2000;14:34-44.
24. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
25. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459-68.
26. Kiuru M, Lehtonen R, Arola J, et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 2002;62:4554-7.
27. Barker KT, Bevan S, Wang R, et al. Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br J Cancer 2002;87:446-8.
28. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998-3002.
29. Teng DH, Bogden R, Mitchell J, et al. Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 1996;13:241-4.
30. Hewitson KS, McNeill LA, Riordan MV, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002;277:26351-5. Epub 2002 May 31.
31. Lando D, Peet DJ, Gorman JJ, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002;16:1466-71.
32. Cheolju L, Seung JK, Dae GJ, et al. Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J Biol Chem 2003;278:7558-63.